(NASDAQ: ADMA) Adma Biologics's forecast annual revenue growth rate of 19.85% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Adma Biologics's revenue in 2025 is $459,381,000.On average, 1 Wall Street analysts forecast ADMA's revenue for 2025 to be $120,751,781,627, with the lowest ADMA revenue forecast at $120,751,781,627, and the highest ADMA revenue forecast at $120,751,781,627. On average, 1 Wall Street analysts forecast ADMA's revenue for 2026 to be $153,076,398,535, with the lowest ADMA revenue forecast at $153,076,398,535, and the highest ADMA revenue forecast at $153,076,398,535.
In 2027, ADMA is forecast to generate $189,483,371,050 in revenue, with the lowest revenue forecast at $189,483,371,050 and the highest revenue forecast at $189,483,371,050.